CTOs on the Move


 
Amwell (previously known as American Well) is a leading telehealth platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The Company offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, behavioral health, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers telehealth solutions for over 240 health systems comprised of 2,000 hospitals and 55 health plan partners with over ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.amwell.com
  • 75 State Street 26th Floor
    Boston, MA USA 02109
  • Phone: 617.204.3500

Executives

Name Title Contact Details
Serkan Kutan
Chief Technology Officer Profile

Funding

Amwell raised $194M on 05/20/2020
Amwell raised $100M on 08/25/2020

Similar Companies

Village Apothecary

Village Apothecary is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harbor Health Elder Service Plan

Harbor Health Elder Service Plan is a Dorchester Center, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Anatomical Chart Company

Anatomical Chart Company is a Skokie, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

WRB Communications

"WRB Communications Inc., a dynamic and innovative company, specializes in the development and management of health information and communications programs. Our programs are provided through the integration of a ""live"" professional staff and cutting edge"

Foghorn Therapeutics

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.